Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485672 | 1.00 | GLP1R (0.56) | GLP1RMEN1KMT2ASIRT6SIRT1 | |
| SCHEMBL16076995 | 0.95 | GLP1R (0.58) | GLP1RSIRT6SIRT1TLR2TSHR | |
| SCHEMBL3484885 | 0.91 | GLP1R (0.54) | GLP1RMEN1KMT2ASIRT6SIRT1 | |
| SCHEMBL4517738 | 0.91 | GLP1R (0.54) | GLP1RMEN1KMT2ASIRT6SIRT1 | |
| SCHEMBL16326834 | 0.91 | GLP1R (0.61) | GLP1RMEN1KMT2ASIRT6SIRT1 | |
| SCHEMBL13699566 | 0.91 | GLP1R (0.58) | GLP1RMEN1KMT2ASIRT6SIRT1 | |
| SCHEMBL5575211 | 0.91 | GLP1R (0.66) | GLP1RMEN1KMT2ASIRT6SIRT1 | |
| SCHEMBL13936570 | 0.91 | GLP1R (0.56) | GLP1RMEN1KMT2ASIRT6SIRT1 | |
| SCHEMBL5575229 | 0.91 | GLP1R (0.66) | GLP1RMEN1KMT2ASIRT6SIRT1 | |
| SCHEMBL16326833 | 0.90 | GLP1R (0.53) | GLP1RMEN1KMT2ASIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-1853321-A2 | INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1843790-A2 | INSULIN DERIVATIVES CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2007-10-17 | — | — | EP | disclosed |
| US-20060198819-A1 | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2006-09-07 | — | — | US | disclosed |
| WO-2006087354-A2 | INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| WO-2006079641-A2 | INSULIN DERIVATIVES CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2006-08-03 | — | — | WO | disclosed |
| EP-1653996-A2 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | Novo Nordisk Health Care AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| EP-1654004-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005014035-A2 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTH CARE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014049-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060198819-A1 | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | GALE, GALNT2, GALNT1 | GLP1R 2352/4885MEN1 4412/4885KMT2A 4257/4885 |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | VIP, PTMS, PDGFA | GLP1R 103/4885MEN1 1142/4885KMT2A 4517/4885 |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | GLP1R 103/4885MEN1 1142/4885KMT2A 4517/4885 |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | GLP1R 2352/4885MEN1 4412/4885KMT2A 4257/4885 |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | INSR, IAPP, IGF1R | GLP1R 14/4885MEN1 278/4885KMT2A 4457/4885 |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | GLP1R 2352/4885MEN1 4412/4885KMT2A 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.